Cited 0 times in
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김유리 | - |
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2023-11-07T07:55:00Z | - |
dc.date.available | 2023-11-07T07:55:00Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196549 | - |
dc.description.abstract | Purpose: This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL). Materials and methods: Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R-CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy. Results: Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent grade 3 adverse events (40.0%) and 5 treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016). Conclusion: Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients. ClinicalTrials.gov ID: NCT01054781. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Cyclophosphamide | - |
dc.subject.MESH | Doxorubicin | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphoma, Large B-Cell, Diffuse* / pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Prednisolone* / adverse effects | - |
dc.subject.MESH | Rituximab / therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vincristine | - |
dc.title | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yu Ri Kim | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.contributor.googleauthor | Hyeon Seok Eom | - |
dc.contributor.googleauthor | Deok-Hwan Yang | - |
dc.contributor.googleauthor | Sung Hwa Bae | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Jae Hoon Lee | - |
dc.contributor.googleauthor | Suk-Joong Oh | - |
dc.contributor.googleauthor | Sung-Soo Yoon | - |
dc.contributor.googleauthor | Jae-Yong Kwak | - |
dc.contributor.googleauthor | Chul Won Choi | - |
dc.contributor.googleauthor | Min Kyoung Kim | - |
dc.contributor.googleauthor | Sung Young Oh | - |
dc.contributor.googleauthor | Hye Jin Kang | - |
dc.contributor.googleauthor | Seung Hyun Nam | - |
dc.contributor.googleauthor | Hyeok Shim | - |
dc.contributor.googleauthor | Joon Seong Park | - |
dc.contributor.googleauthor | Yeung-Chul Mun | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Korean Society of Hematology Lymphoma Working Party | - |
dc.identifier.doi | 10.4143/crt.2023.271 | - |
dc.contributor.localId | A00779 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 36996864 | - |
dc.subject.keyword | Diffuse large B-cell lymphoma | - |
dc.subject.keyword | R-CHOP | - |
dc.subject.keyword | Response | - |
dc.subject.keyword | Rituximab | - |
dc.contributor.alternativeName | Kim, Yu Ri | - |
dc.contributor.affiliatedAuthor | 김유리 | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 55 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1355 | - |
dc.citation.endPage | 1362 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.55(4) : 1355-1362, 2023-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.